Menu

Opinion: Develop Organoids, Not Chimeras, for Transplantation

Scientists are devising human-animal hybrids for harvesting human organs, but lab-derived mini-organs are a less ethically fraught solution to meeting the need for transplantation.

Aug 23, 2019
John D. Loike, Robert Pollack

ABOVE: © ISTOCK.COM, SEAMARTINI

Recent studies have shown that even though about 50 percent of adults in the United States have registered as organ donors, more than 100,000 people in the United States are waiting for a transplant and many will die waiting. The increasing scarcity of human organ donors has driven research scientists to examine other options, such as xenotransplantation, to generate essential human transplantable organs. 

Xenotransplantation experiments, generating human organs in animals for transplantation, are being conducted in sheep, pigs, and, recently, in nonhuman primates. Last month, a group of scientists from Spain and the US began to examine the use of monkeys as animal hosts to produce human organs. According to the published reports, the research was conducted in China “to avoid legal issues.” Xenotranplantation experiments rely on applying gene editing and stem cell biology technologies to address the potential of tissue rejection by the recipient’s immune system and the possibility of transmitting infectious diseases from donor animals to the human recipients. Scientists are years away from solving technical hurdles, such as developing a human vascular system in these organs, before beginning clinical trials in human beings. 

There is an alternative that we believe avoids several of these scientific and ethical concerns—the use of stem cell technology to develop human organoids.

There are many scientific and ethical issues emerging from xenotransplantation technologies. For example, will it be ethical to do the experiments necessary to ensure that human stem cells introduced into the animal embryo to form a kidney will not migrate to the animal’s brain to generate human-like behaviors in such animal chimeras?  

There have been several studies showing that the expression of human genes in animal brains affect behavior. In April of 2019, scientists in China published a study in which they claimed to have introduced a DNA sequence expressed in human brains into monkeys, and found the animals had better short-term memory and shorter reaction times than control animals. Even though these animals were not chimeras as xenotransplantation hosts would be, it is clear that new ethical boundaries are being pushed in animal studies. To date, no human-animal hybrid embryos have been brought to term and the US National Institutes of Health has had a moratorium on funding such work since 2015. 

Some ethicists have argued that because these animal-human chimeras will be sacrificed for their human organs at birth there is no need to be ethically concerned that their nervous systems might develop any human traits. We believe this argument does not adequately address the ethical issue. By accepting the necessity of their destruction as an element of xenotransplantation research, scientists would have had to decide in advance that the potential personhood of human-animal chimeras could be ignored for the short run, leaving open the possibility of a later discovery that such chimeras might in fact have human traits. 

Equally important is the trend in many countries, such as Argentina, that recognize personhood status of nonhuman primates and ban their “incarceration” in zoos. Human-monkey chimeras would properly have even greater or enhanced personhood status than normal monkeys.

Ethicists also may argue that the need to address the organ transplant crisis may override our ethical debates on whether such chimeras are human-like or whether they have personhood status. That argument has merit, but even if the debate were to be set aside, that decision would not justify the use of a technology that is still full of unanswered questions.

There is an alternative that we believe avoids several of these scientific and ethical concerns—the use of stem cell technology to develop human organoids. We have seen a great deal of excitement following the development of artificial ovaries for women with cancer who had been treated with high-dose chemotherapy. The potential fear of being infertile from these treatments can be mitigated by developing artificial ovaries from their own stem cells, after these young women are cured of their cancers. 

There are other scientific groups that are using 3-D technologies to develop mini-organs such as liver, placenta, stomach, lymph nodes, and even brain. As with artificial ovaries, organs can be removed from patients and their cells can be gently destroyed with detergent, leaving behind a translucent matrix that serves as a platform for organ-directed pluripotent cells to differentiate into new organ-specific cells in vivo. These stem cells can further develop into organoid structures within weeks as opposed to the months required to develop human organs in pigs, sheep, or monkeys. Organovo recently presented new findings on its stem cell–based approach to developing kidney tissue using its 3-D bioprinting platform. The company reported that the automated production of complex kidney organoids has potential future applications including in vitro disease modeling and in the treatment of patients with renal disease. 

Currently, most of the scientists in the field are using human organoids to study human disease, but these tissues have the potential to serve as organ transplants. Using human organoids in transplants will avoid the basic problems of tissue rejection and the possible introduction of pathogens or oncogenes from animals into human recipients. Equally important, there is less concern that human non-brain organoids will generate new CNS neurons that could alter the behaviors of their recipients. 

Without making a final ethical judgment on future research using human-animal chimeras as a source of human transplantable organs, we believe that developing human organoids might offer a faster and better scientific and ethical platform to address the crisis in organ transplantation.    

John D. Loike, a professor of biology at Touro College and University Systems, writes a regular column on bioethics for The ScientistRobert Pollack is a professor of biological sciences at Columbia University.

September 2019

Our Inner Neanderthal

Ancient secrets in the human genome

Marketplace

Sponsored Product Updates

Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Download this application note to learn how the ACEA xCELLigence system can evaluate the potency of an immunotherapy against a broad spectrum of liquid tumors and monitor the destruction kinetics of liquid cancers at physiologically relevant effector:target cell ratios.
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Watch this webinar to learn how Dr. Cara Haymaker and her team are assessing the reactivity of tumor-infiltrating lymphocytes and modulating the mechanisms of resistance to therapy and exploring biomarkers involved in the response.
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs). Portfolio includes novel CIMasphere™ technology for higher yielding processes and safer products in AAV-based programs